Johnson & Johnson (NYSE:JNJ) Trading Up 1.5% – What’s Next?

Johnson & Johnson (NYSE:JNJ) shares rose 1.5% during mid-day trading on Wednesday . The stock traded as high as $203.48 and last traded at $203.04. Approximately 14,662,227 shares traded hands during trading, an increase of 65% from the average daily volume of 8,878,454 shares. The stock had previously closed at $200.00.

Analyst Ratings Changes

A number of research analysts recently commented on JNJ shares. Loop Capital set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 22nd. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research report on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Trading Up 1.5%

The firm’s 50-day moving average price is $186.69 and its 200 day moving average price is $170.77. The company has a market cap of $489.18 billion, a price-to-earnings ratio of 19.60, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of large investors have recently modified their holdings of JNJ. SOA Wealth Advisors LLC. lifted its position in Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after buying an additional 53 shares in the last quarter. Ethos Financial Group LLC raised its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after acquiring an additional 53 shares during the last quarter. Pinnacle Holdings LLC lifted its position in shares of Johnson & Johnson by 0.5% during the third quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after purchasing an additional 54 shares in the last quarter. Bouchey Financial Group Ltd grew its stake in shares of Johnson & Johnson by 0.8% during the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock valued at $1,344,000 after purchasing an additional 54 shares during the last quarter. Finally, Intrepid Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 0.4% in the third quarter. Intrepid Capital Management Inc. now owns 12,785 shares of the company’s stock valued at $2,371,000 after purchasing an additional 54 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.